N-Boc-2-(4-bromophenyl)ethylamine
CAS : 120157-97-3
Ref. 3D-VEA15797
1g | Arrêté | ||
5g | Arrêté | ||
10g | Arrêté | ||
50mg | Arrêté | ||
250mg | Arrêté | ||
500mg | Arrêté | ||
1000mg | Arrêté | ||
5000mg | Arrêté | ||
10000mg | Arrêté |
Informations sur le produit
- 1,1-Dimethylethyl N-[2-(4-bromophenyl)ethyl]carbamate
- 2-(4-Bromophenyl)-N-(t-butoxycarbonyl)ethylamine
- Carbamic acid, N-[2-(4-bromophenyl)ethyl]-, 1,1-dimethylethyl ester
- Carbamic acid, [2-(4-bromophenyl)ethyl]-, 1,1-dimethylethyl ester
- N-Boc-4-Bromophenethylamine
- N-Boc-P-Bromophenethyl Amine
- N-[2-(4-Bromophenyl)ethyl]carbamic acid tert-butyl ester
- N-tert-Butoxycarbonyl-2-(4-bromophenyl)ethylamine
- Tert-Butyl 4-Bromophenethylcarbamate
- Tert-Butyl [2-(4-Bromophenyl)Ethyl]Carbamate
- Voir d'autres synonymes
- [2-(4-Bromo-Phenyl)-Ethyl]-Carbamic Acid Tert-Butyl Ester
- tert-Butyl N-[2-(4-bromophenyl)ethyl]carbamate
N-Boc-2-(4-bromophenyl)ethylamine is a hydroxylase inhibitor. It acts as a competitive inhibitor of the enzyme hydroxylase, which is involved in the synthesis of the neurotransmitter catecholamines (such as dopamine and norepinephrine). The binding site for N-Boc-2-(4-bromophenyl)ethylamine on the hydroxylase enzyme has been identified as the iron atom in heme group of cytochrome P450. Inhibition of this hydroxylation results in lower levels of catecholamines, which can be beneficial for diseases such as Parkinson's disease, Alzheimer's disease and schizophrenia. This drug has also been shown to have an inhibitory effect on other enzymes such as adenosine receptors, adenosine monophosphate (AMP), and monoamine oxidase type A (MAO-A).